RxDoctor Payments Data
★ My doctorsLook up a doctor →

Jorge Cuello

Cardiovascular Disease · South Miami, FLNPI 1003855511

Payments from drug & device makers

$3,532in general payments, 2019–2025

Across 217 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$697
  • Medtronic$456
  • Abbott$347
  • E.r. Squibb & Sons, L.L.C.$296
  • Amgen$275
  • Pfizer$202
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,46098%
  • Education$722%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson73$697
Medtronic(2 entities)21$456
Abbott14$347
E.r. Squibb & Sons, L.L.C.15$296
Amgen17$275
Pfizer11$202
Amarin Pharma, Inc.10$177
Kowa Pharmaceuticals America, Inc.8$169
Gilead8$117
Avanir Pharmaceuticals, Inc.1$109
Sanofi-aventis U.S. LLC6$107
Novartis6$106
Novo Nordisk7$101
Arbor Pharmaceuticals, Inc.6$77
Biotronik Inc.1$72
Regeneron Healthcare Solutions, Inc.3$40
Esperion Therapeutics, Inc.2$36
Cardiva Medical, Inc.1$34
Boston Scientific2$33
Alnylam Pharmaceuticals Inc.1$21
Kiniksa Pharmaceuticals, Ltd.1$16
Azurity Pharmaceuticals, Inc.1$16
Actelion Pharmaceuticals US, Inc.1$15
AstraZeneca1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,532 in reported general payments places this provider in the 50th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida →

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$45,143
XareltoRivaroxaban29$26,937
EntrestoSacubitril/Valsartan18$23,970
Metoprolol Succinate98$1,131
Atorvastatin Calcium52$427
Olmesartan Medoxomil18$391
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid17$321
Losartan Potassium17$292
Rosuvastatin Calcium29$274
Digoxin19$246
Amlodipine Besylate35$207
Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril15$195
Pantoprazole Sodium19$191
Metoprolol Tartrate14$186
Hydralazine Hcl22$135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$202$45,14341 claims
Johnson & JohnsonXarelto$697$26,93729 claims
NovartisEntresto$106$23,97018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in South Miami

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →